Bausch + Lomb to Present 28 Scientific Studies at Academy 2026 Anaheim

Bausch + Lomb to Present 28 Scientific Studies at Academy 2026 Anaheim

• Presentations will feature clinical, real-world and patient experience data across Bausch + Lomb pharmaceutical, contact lens and consumer eye care products
• New Phase 4 research evaluated MIEBO^® (perfluorohexyloctane ophthalmic solution) during contact lens wear
• Real-world studies evaluated concomitant XIIDRA^® (lifitegrast ophthalmic solution) 5% and MIEBO therapy in patients with dry eye disease
• Studies highlighted rapid and durable redness relief with a novel formulation of LUMIFY^® redness reliever eye drops containing hyaluronic acid

VAUGHAN, Ontario, Sept. 28, 2026 - Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced 28 poster presentations at Academy 2026 Anaheim, the American Academy of Optometry's annual meeting, in Anaheim, Calif., Sept. 30 to Oct. 3, 2026. The company will also host several educational events during the meeting.

Scientific posters will feature data from clinical, real-world and patient experience studies across the company's broad portfolio of pharmaceutical, contact lens and consumer eye care products. Featured presentations include patient experience assessments of MIEBO during contact lens wear, including measures of contact lens performance and tolerability; real-world evaluations of concomitant XIIDRA and MIEBO therapy in patients with dry eye disease, including assessments of disease signs and symptoms; and studies highlighting rapid and durable redness relief with a novel formulation of LUMIFY redness reliever eye drops containing hyaluronic acid.

Sponsored educational events will focus on topics such as dry eye management and the role of B vitamins in supporting macular health. These events will feature products including MIEBO, XIIDRA, Blink^® NutriTears^® supplement for dry eyes, PreserVision AREDS3™ eye vitamins and LUMIFY^® redness reliever eye drops.

Below is a complete list of Bausch + Lomb scientific presentations and events.

Poster Presentations

• "Lifitegrast Ophthalmic Solution in Patients with Dry Eye Disease: Real-World Evidence from a Provider Survey and a Pharmacovigilance Database." Barnett M.
• "Performance of a Novel Silicone Hydrogel Daily Disposable Multifocal Contact Lens Among Prior Delefilcon a Multifocal Wearers." Bhagat K
• "Assessing Dry Eye Symptoms and Impact of Vision-related Functioning in Patients with Dry Eye Disease Using Perfluorohexyloctane Ophthalmic Solution." Bloomenstein M.
• "Patterns of Adherence to Latanoprostene Bunod 0.024% in Medicare Patients with Comorbid Dry Eye Disease in Real-World Settings." Bruns N.
• "Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%: Results from a Pharmacovigilance Database." Cothran N.
• "Randomized, Double-Masked Comparison of Ocular Tolerability and Patient Preference for Fluorometholone Acetate Suspension vs Loteprednol Etabonate Gel." Davidson J.
• "Comparative Efficacy of FDA-Approved Therapies for Dry Eye Disease: A Systematic Review and Network Meta-analysis of Schirmer's Test Outcomes." Diamanti S.
• "Preservative Toxicity to Biometric Reliability: Ocular Surface Optimization with Cryopreserved Amniotic Membrane Before Cataract and Glaucoma Surgery." Flynn A.
• "Real-World Healthcare Utilization and Treatment Patterns Following a New Dry Eye Disease Diagnosis: A Retrospective Claims Analysis (2017-2024)." Hassan T.
• "Treatment Sequencing and Adherence with DED-Specific Therapies in Newly Diagnosed DED Patients: Real-World Evidence from a Large US Claims Database." Hassan T.
• "Embedded Eyelashes and Acquired Trichiasis Associated with Cosmetic Eyelash Serum Use." Hatami L.
• "Real-World Outcomes in Patients Transitioning from Monovision to Monthly Multifocal Toric Lenses: A Case Series." Hoffman K.
• "Global Post-Marketing Safety Experience with Brimonidine Tartrate Ophthalmic Solution 0.025%." Kannarr S.
• "Prospective Open-Label Trial Evaluating Concomitant Use of Perfluorohexyloctane Ophthalmic Solution with Contact Lens Wear." Kannarr S.
• "Changing Landscapes: Impression-Based Scleral Lens Adaptation to Sequential Glaucoma Surgical Anatomy in a Corneal Graft Patient." Khan S.
• "Burden of Illness of Bacterial Conjunctivitis in the United States Using the Medical Expenditure and Panel Survey." Koetting C.
• "Clinical Outcomes with Topical Latanoprostene Bunod in Patients with Open-Angle Glaucoma or Ocular Hypertension: A Retrospective Real-World Study." Koetting C.
• "Qualitative Survey of Eye Care Providers: What Defines Robust Response to Lifitegrast in Dry Eye Disease?." Lang J.
• "Rapid and Durable Redness Relief with a Novel Brimonidine Tartrate Ophthalmic Solution Containing Hyaluronic Acid." Lang J.
• "Real-World Improvements in Dry Eye Disease Signs and Symptoms with Concomitant Lifitegrast and Perfluorohexyloctane Therapy." Lee B.
• "Latanoprostene Bunod 0.024% Initiation in Medicare Fee-for-Service Patients with Open Angle Glaucoma and Ocular Hypertension." Lievens C.
• "Real-World Impact of Treatment Switch to Latanoprostene Bunod on Intraocular Pressure in Glaucoma Patients: An IRIS Registry Study." Nair A.
• "Real-World Satisfaction and Experience with a Novel Daily Disposable Toric Contact Lens Among Wearers Experiencing Frequent Halos and Glare." Nguyen C.
• "Beyond Antioxidants: Reevaluating B Vitamins in Retinal and Ocular Surface Disorders." Poteet J.
• "Concomitant Use of Perfluorohexyloctane and Lifitegrast in Dry Eye Disease Management: Results from a Nationwide Survey of Eyecare Providers." Quint J.
• "Real-World Assessment of a Multi-Purpose Contact Lens Solution Among Habitual Samfilcon a Monthly Replacement Contact Lens Wearers." Schaeffer M.
• "Immediate and Sustained Symptom Relief with a Lipid-Hyaluronic Acid Eye Drop: Evidence from Randomized and Real-World Studies." Seitz E.
• "Real-World Performance and Practitioner Satisfaction with a Toric Kalifilcon a Daily Disposable Lens." Wesley G.

Educational Events
Wednesday, September 30
Case Symposium: A Family of Eye Care Products with Innovations for Every Stage of Life

• 12:00-1:00 p.m. PT; Anaheim Convention Center, 800 W Katella Avenue, Anaheim, CA 92802, North Level/200, Room: 212
• Speakers: Casey Claypool, OD; Mile Brujic, OD, FAAO

Redness Relief with Purpose: Clinical Context, Patient Impact and the Role of LUMIFY

• 5:30-6:30 p.m. PT; Anaheim Convention Center, 800 W Katella Avenue, Anaheim, CA 92802, North Level/200, Room: 212
• Speaker: Selina McGee, OD, FAAO

Thursday, October 1
A Foundational Approach to Dry Eyes Symptom Relief

• 8:00-8:45 a.m. PT; Anaheim Convention Center, 800 W Katella Avenue, Anaheim, CA 92802, North Level/200, Room: 251 B
• Speaker: Jesslin Quint, OD, FAAO

Pathways in Optometry: The Many Ways to Make a Difference

• 11:30 a.m. - 1:30 p.m. PT; Anaheim Marriott, 700 W. Convention Way, Anaheim, CA 92802, Room: Marquis Ballroom
• Speaker: Jill Saxon, OD, FAAO

Fast Tracking Dry Eye Management: Integrating Science and Practice

• 12:00-1:00 p.m. PT; Anaheim Convention Center, 800 W Katella Avenue, Anaheim, CA 92803, North Level/200, Room: 215 B
• Speakers: Chris Lievens, OD; Mitch Ibach, OD

PreserVision AREDS3 Eye Vitamins: An Updated Nutrient Formula

• 5:30-6:30 p.m. PT; Anaheim Convention Center, 800 W Katella Avenue, Anaheim, CA 92802, North Level/200, Room: 212
• Speakers: Jeffry D. Gerson, OD, FAAO

Friday, October 2
The Puzzle of Dry Eye: Targeted Approaches to a Multifactorial Condition

• 12:00-1:00 p.m. PT; Anaheim Convention Center, 800 W Katella Avenue, Anaheim, CA 92802, North Level/200, Room: 251 B
• Speakers: Ada Noh, OD; Shane Kannarr, OD

###

MIEBO Indications and Important Safety Information

INDICATION
MIEBO^® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

• MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
• MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
• Instruct patients to instill one drop of MIEBO into each eye four times daily
• The safety and efficacy in pediatric patients below the age of 18 have not been established
• In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Click here for full Prescribing Information for MIEBO.

XIIDRA Indications and Important Safety Information

Indication
Xiidra^® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

• Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
• In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
• To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
• Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
• Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for full Prescribing Information for Xiidra.

VYZULTA Indications and Important Safety Information

INDICATION
VYZULTA^® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

• Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
• Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
• Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
• Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
• There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
• Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
• Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

Please click here to see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch or call 1-800-FDA-1088.

About Bausch + Lomb
Our mission is simple - we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we're turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

©2026 Bausch + Lomb.
MTB.0446.USA.26

Media Contacts:
Kristy Marks
[email protected]
(908) 927-0683

Caryn Marshall
[email protected]
(908) 493-1381